NEW DELHI: A wave of affordable generic versions of Ozempic and Wegovy (semaglutide) has rapidly captured around 20% of the nearly Rs 1,600 crore weight-loss market within days of launch, following ...
Dublin, April 10, 2026 (GLOBE NEWSWIRE)-- The "US FDA - Understanding Key Factors When Working with the FDA (May 12, 2026)" training has been added to ResearchAndMarkets.com's offering. This course ...
LOWERING DRUG COSTS — Bipartisan lawmakers have revived efforts to require Medicare to cover generic drugs — and at least two biosimilars — with patients paying lower costs than for brand-name drugs, ...
The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...
The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...
March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...
The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results